Nanobiotix Sa Stock Fundamentals
| NANO Stock | EUR 2.95 0.01 0.34% |
Nanobiotix SA fundamentals help investors to digest information that contributes to Nanobiotix's financial success or failures. It also enables traders to predict the movement of Nanobiotix Stock. The fundamental analysis module provides a way to measure Nanobiotix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanobiotix stock.
Nanobiotix |
Nanobiotix SA Company Return On Equity Analysis
Nanobiotix's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nanobiotix Return On Equity | -1.99 |
Most of Nanobiotix's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanobiotix SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nanobiotix SA has a Return On Equity of -1.9869. This is 91.71% lower than that of the Healthcare sector and 192.41% lower than that of the Drug Manufacturers - Major industry. The return on equity for all France stocks is notably higher than that of the company.
Nanobiotix SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nanobiotix's current stock value. Our valuation model uses many indicators to compare Nanobiotix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanobiotix competition to find correlations between indicators driving Nanobiotix's intrinsic value. More Info.Nanobiotix SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanobiotix by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanobiotix's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nanobiotix Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanobiotix's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanobiotix could also be used in its relative valuation, which is a method of valuing Nanobiotix by comparing valuation metrics of similar companies.Nanobiotix is currently under evaluation in return on equity category among its peers.
Nanobiotix Fundamentals
| Return On Equity | -1.99 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (17.96) % | |||
| Current Valuation | 111.08 M | |||
| Shares Outstanding | 34.88 M | |||
| Shares Owned By Insiders | 3.78 % | |||
| Shares Owned By Institutions | 25.56 % | |||
| Price To Earning | (12.17) X | |||
| Price To Book | 71.98 X | |||
| Price To Sales | 48.04 X | |||
| Revenue | 10 K | |||
| Gross Profit | 2.65 M | |||
| EBITDA | (44.85 M) | |||
| Net Income | (47 M) | |||
| Cash And Equivalents | 36.2 M | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 35.56 M | |||
| Debt To Equity | 144.00 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (29.87 M) | |||
| Earnings Per Share | (1.20) X | |||
| Target Price | 14.9 | |||
| Number Of Employees | 103 | |||
| Beta | 1.8 | |||
| Market Capitalization | 115.07 M | |||
| Total Asset | 101.77 M | |||
| Retained Earnings | (17 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 23 M | |||
| Current Liabilities | 7 M | |||
| Z Score | 1.8 | |||
| Net Asset | 101.77 M |
About Nanobiotix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanobiotix SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanobiotix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanobiotix SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nanobiotix Stock
Nanobiotix financial ratios help investors to determine whether Nanobiotix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanobiotix with respect to the benefits of owning Nanobiotix security.